By Colin Kellaher
Roche Holding AG's Genentech unit on Monday said a phase 3 study of Tecentriq in advanced-stage ovarian cancer missed a main endpoint.
Genentech said the addition of Tecentriq to Avastin, paclitaxel and carboplatin didn't meet its primary endpoint of progression-free survival for the front-line treatment of women with newly diagnosed advanced-stage ovarian cancer.
Genentech said it is disappointed by the study results, adding that ovarian cancer is one of the most aggressive cancers and is difficult to treat in its advanced stages.
The company said data for the overall survival co-primary endpoint are currently immature, and that follow-up will continue until the next planned analysis.
Genentech noted that it has an extensive development program for Tecentriq, including multiple ongoing and planned phase III studies across several cancers.
Write to Colin Kellaher at firstname.lastname@example.org